1. Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis 
A. Kyvernitakis, H.A. Torres, Y. Jiang, G. Chamilos, R.E. Lewis, D.P. Kontoyiannis 
Clinical Microbiology and Infection 
Volume 22, Issue 9, Pages 811.e1-811.e8 (September 2016)
DOI: /j.cmi
Copyright © 2016 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

2. Fig. 1
Annual incidence and deaths from mucormycosis in patients with haematologic malignancies.
Clinical Microbiology and Infection  , 811.e1-811.e8DOI: ( /j.cmi )
Copyright © 2016 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

3. Fig. 2
Propensity score–adjusted survival curves for patients with haematologic malignancies and mucormycosis treated with monotherapy or combination treatment (p 0.71).
Clinical Microbiology and Infection  , 811.e1-811.e8DOI: ( /j.cmi )
Copyright © 2016 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

4. Fig. 3
Kaplan-Meier survival curves according to assigned mortality risk scores for patients with haematologic malignancies and mucormycosis treated with monotherapy or combination treatment. Shown are data from patients at low risk for mortality (risk score, <33; p 0.78) and patients at high risk for mortality (risk score, >33; p 0.35).
Clinical Microbiology and Infection  , 811.e1-811.e8DOI: ( /j.cmi )
Copyright © 2016 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

5. Clinical Microbiology and Infection 2016 22, 811. e1-811. e8DOI: (10
Clinical Microbiology and Infection  , 811.e1-811.e8DOI: ( /j.cmi )
Copyright © 2016 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions